CEO Interviews

More Interviews

Greenwich LifeSciences (NASDAQ: GLSI)

GLSI Interview

Greenwich: Phase 3 Trial Actively Enrolling Patients Targeting Breast Cancer Recurrence

Greenwich LifeSciences (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.

 Play

Reviva (NASDAQ: RVPH)

RVPH Interview

Reviva: Announcing Completion of Enrollment of Pivotal Phase 3 Trial

Reviva (NASDAQ: RVPH) is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house.

 Play

BullFrog AI (NASDAQ: BFRG)

BFRG Interview

Revolutionizing Medicine: A Conversation with BullFrog AI's CEO on AI-Driven Drug Development

BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development.

 Play

BioVie (NASDAQ: BIVI)

BIVI Interview

In the Spotlight: BioVie's (NASDAQ: BIVI) Quest to Tackle Alzheimer's, Parkinson's, and More

BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) and BIV201 for Refractory Ascites and HRS-AKI.

 Play

Rail Vision (NASDAQ: RVSN)

RVSN Interview

Rail Vision: Revolutionizing Rail Safety Using A.I.

Rail Vision (NASDAQ: RVSN) is the leading provider of obstacle detection and classification systems in the railway industry. With the Company’s unique cognitive sensor fusion technology, based on advanced electro-optic sensors, artificial intelligence and deep learning, Rail Vision systems detect objects on and along the tracks from a distance of up to two kilometers – in real time – as well as in all weather and light conditions.

 Play


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market